Stryker Corporation $SYK Stock: Modera Wealth Management LLC Lowers Holdings

Modera Wealth Management LLC reduced its position in shares of Stryker Corporation (NYSE:SYK) by 5.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,616 shares of the medical technology company’s stock after selling 2,201 shares during the quarter. Modera Wealth Management LLC’s holdings in Stryker were worth $10,635,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Gables Capital Management Inc. bought a new stake in shares of Stryker in the 2nd quarter valued at about $25,000. Kilter Group LLC bought a new position in Stryker during the second quarter worth about $25,000. Cornerstone Financial Management LLC grew its holdings in Stryker by 66.0% during the second quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after purchasing an additional 31 shares during the period. Highland Investment Advisors LLC bought a new position in Stryker during the second quarter worth about $25,000. Finally, Compass Financial Management LLC acquired a new position in Stryker during the second quarter worth approximately $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of research analyst reports. Canaccord Genuity Group cut shares of Stryker from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $385.00 to $300.00 in a research report on Friday. Needham & Company LLC dropped their price objective on shares of Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a research report on Friday. Wells Fargo & Company cut their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research note on Wednesday, September 9th. TD Cowen reduced their target price on shares of Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a report on Friday. Finally, Argus set a $370.00 price target on shares of Stryker in a research note on Thursday, July 9th. Sixteen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $355.84.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 351,267 shares of company stock worth $118,197,701 in the last quarter. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

Shares of NYSE SYK opened at $291.56 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock’s fifty day moving average price is $292.83 and its two-hundred day moving average price is $324.51. Stryker Corporation has a one year low of $267.00 and a one year high of $389.33. The firm has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a P/E/G ratio of 2.01 and a beta of 0.78.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, October 29th. The medical technology company reported $3.52 earnings per share for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The firm had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.83% and a net margin of 13.78%. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.19 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.93 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date was Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Trending Headlines about Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.